Pfizer (NYSE:PFE) Sets New 12-Month Low at $25.20

Shares of Pfizer Inc. (NYSE:PFE) reached a new 52-week low on Friday . The stock traded as low as $25.20 and last traded at $25.45, with a volume of 5205277 shares traded. The stock had previously closed at $25.26.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a research report on Thursday, January 4th. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. Finally, Guggenheim assumed coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target on the stock. Eleven research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $36.33.

Pfizer Price Performance

The business has a fifty day moving average of $26.96 and a 200-day moving average of $28.39. The firm has a market cap of $143.83 billion, a PE ratio of 70.56, a PEG ratio of 1.14 and a beta of 0.61. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm’s quarterly revenue was down 41.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.14 EPS. As a group, research analysts predict that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be issued a dividend of $0.42 per share. The ex-dividend date is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a yield of 6.61%. Pfizer’s dividend payout ratio (DPR) is 466.67%.

Hedge Funds Weigh In On Pfizer

A number of institutional investors have recently added to or reduced their stakes in the business. Hourglass Capital LLC increased its stake in Pfizer by 2.2% in the 1st quarter. Hourglass Capital LLC now owns 281,560 shares of the biopharmaceutical company’s stock worth $7,813,000 after acquiring an additional 5,950 shares during the last quarter. Foster Victor Wealth Advisors LLC increased its stake in Pfizer by 12.6% in the 1st quarter. Foster Victor Wealth Advisors LLC now owns 411,942 shares of the biopharmaceutical company’s stock worth $10,851,000 after acquiring an additional 45,987 shares during the last quarter. K.J. Harrison & Partners Inc increased its stake in Pfizer by 179.2% in the 1st quarter. K.J. Harrison & Partners Inc now owns 116,713 shares of the biopharmaceutical company’s stock worth $3,239,000 after acquiring an additional 74,912 shares during the last quarter. Members Advisory Group LLC bought a new position in Pfizer in the 1st quarter worth about $584,000. Finally, Plan Group Financial LLC increased its stake in Pfizer by 54.6% in the 1st quarter. Plan Group Financial LLC now owns 15,124 shares of the biopharmaceutical company’s stock worth $420,000 after acquiring an additional 5,339 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.